Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Cash Flow (2016 - 2025)

Seres Therapeutics' Net Cash Flow history spans 11 years, with the latest figure at $2.3 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 151.25% year-over-year to $2.3 million; the TTM value through Sep 2025 reached -$20.4 million, up 79.89%, while the annual FY2024 figure was -$96.7 million, 175.72% down from the prior year.
  • Net Cash Flow for Q3 2025 was $2.3 million at Seres Therapeutics, up from -$13.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $153.5 million in Q3 2021 and bottomed at -$68.2 million in Q1 2023.
  • The 5-year median for Net Cash Flow is -$26.4 million (2022), against an average of -$3.1 million.
  • The largest annual shift saw Net Cash Flow plummeted 455.46% in 2022 before it skyrocketed 610.76% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at -$39.5 million in 2021, then dropped by 7.38% to -$42.4 million in 2022, then increased by 1.0% to -$41.9 million in 2023, then grew by 11.23% to -$37.2 million in 2024, then surged by 106.07% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Net Cash Flow are $2.3 million (Q3 2025), -$13.5 million (Q2 2025), and $28.1 million (Q1 2025).